Galux
Seoul, Seoul, South Korea · Artificial Intelligence, Biotechnology
Galux is a South Korean biotech company that specializes in AI-driven protein therapeutics discovery. The company is focused on developing innovative solutions for precise protein design in therapeutic applications. Its advanced AI platforms aim to tackle challenges in molecular design and optimize the development of targeted therapies.
Key facts
- Headquarters
- Seoul, Seoul, South Korea
- Employees
- Unknown
- Industries
- Artificial Intelligence, Biotechnology
- Status
- Private
- Website
- galux.co.kr
- Company page
Recent activity at Galux
- : Galux Appoints Park Tae-yong as New Chief Executive Officer
- : Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery. This funding will enhance its AI platform and drug discovery capabilities.
- : Galux Signs Research Agreement with Boehringer Ingelheim to Enhance AI-Driven Protein Design.
Galux funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Series B | $29.0M |
Leadership
- Kim Sung-hyun, Chief Financial Officer
- Park Tae-yong, Chief Executive Officer
- Chaok Seok, Chief Executive Officer
- Taeyong Park, Executive Vice President
Verified email and direct lines for Galux’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Galux in the news
- Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design - Business Wire (Dec 17, 2025)
- Galux Makes the Forbes Asia 100 to Watch 2026 List - Yahoo Finance (Aug 26, 2026)
- Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design - Business Wire (Nov 26, 2025)
Companies similar to Galux
- RITTER PHARMACEUTICALS INC · Artificial Intelligence, Biotechnology
- Inner Logic · Artificial Intelligence, Biotechnology
- DeepCyte · Artificial Intelligence, Biotechnology
- Sightera · Artificial Intelligence, Biotechnology
- mediworkAI · Artificial Intelligence, Biotechnology
About Galux: questions and answers
What does Galux do?
Galux is a South Korean biotech company that specializes in AI-driven protein therapeutics discovery. The company is focused on developing innovative solutions for precise protein design in therapeutic applications. Its advanced AI platforms aim to tackle challenges in molecular design and optimize the development of targeted therapies.
Where is Galux headquartered?
Galux is headquartered in Seoul, Seoul, South Korea.
Has Galux raised funding?
Yes. Fundz has recorded 1 funding event for Galux. The most recent, Series B of $29.0M, was in Feb 2026.
Who leads Galux?
Park Tae-yong is a Chief Executive Officer at Galux.
What is the latest news on Galux?
On Jul 28, 2026, Galux Appoints Park Tae-yong as New Chief Executive Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy